Longevity and Metabolic Reset

How a 5-day low-calorie protocol mimics the cellular effects of a water fast while remaining sustainable — and what the clinical evidence shows for aging, metabolic health, and disease risk.

The fasting mimicking diet (FMD) is a structured 5-day eating protocol — low in calories, protein, and carbohydrates but rich in healthy fats — designed to trigger the same cellular repair processes as extended fasting without requiring complete abstinence from food [1]. It is typically done once per month or once per quarter, followed by a normal eating period. Human clinical trials show that three to four monthly cycles can reduce biological age markers, lower IGF-1, decrease body fat and blood pressure, and improve insulin sensitivity — all without severe caloric restriction [4]. Unlike daily dietary changes, the FMD works by creating a temporary fasting state that activates autophagy, stem cell regeneration, and immune renewal [2].

How the Fasting Mimicking Diet Works

The core concept is that the body's protective and regenerative pathways — autophagy, stem cell activation, reduction in growth-promoting hormones — are largely triggered by nutrient sensing, not by the complete absence of food. When calories, protein (particularly branched-chain amino acids), and carbohydrates fall below certain thresholds for several consecutive days, the body responds as if fasting, even if some food is consumed [1].

The FMD as developed by Valter Longo at USC involves a 5-day protocol:

Day 1: approximately 1,090 calories (10% protein, 56% fat, 34% carbohydrate)
Days 2–5: approximately 725 calories each (9% protein, 44% fat, 47% carbohydrate)
Food sources are plant-based: vegetable soups, nut bars, olives, herbal teas, and supplements

After the 5 days, normal eating resumes for 25+ days. This cycling approach is key — the regenerative signals are triggered during the fast-like period, and recovery and rebuilding happen during the refeeding phase [2].

Key Cellular Mechanisms

IGF-1 reduction: Insulin-like growth factor 1 (IGF-1) promotes cellular growth but also accelerates aging when chronically elevated. Three FMD cycles reduced IGF-1 by an average of 24% in clinical trial subjects [4]. Lower IGF-1 is associated with longevity in multiple species.

Autophagy induction: During nutrient deprivation, cells initiate autophagy — the breakdown and recycling of damaged organelles and misfolded proteins. This cellular "housekeeping" process is strongly implicated in cancer prevention and protection against neurodegeneration [1].

Stem cell regeneration: Mouse studies showed that FMD cycles promote regeneration of hematopoietic (blood-forming) stem cells and gut stem cells. After refeeding, these newly generated cells repopulate tissues including the immune system [2].

Immune rejuvenation: Repeated FMD cycles in mice led to measurable rejuvenation of the immune system, reducing the ratio of myeloid to lymphoid cells — a ratio that increases with aging and indicates immune decline [6].

Practical Protocol

The FMD is most accessible via the commercially available ProLon kit developed at USC, though it can be replicated with whole foods following the macronutrient targets. For healthy adults, monthly cycles are typically studied; for those at metabolic risk, the evidence for 3 consecutive monthly cycles is strongest [4].

The diet is generally well tolerated. The most commonly reported side effects are fatigue and hunger on days 2–3, which tend to decrease with subsequent cycles. It is not appropriate for people who are underweight, pregnant, diabetic without medical supervision, or who have a history of eating disorders.

See our intermittent fasting page for related approaches to time-restricted eating and alternate-day fasting.

Evidence Review

Foundational Animal and Mechanistic Research

Longo and Mattson (2014) published a comprehensive review in Cell Metabolism establishing the molecular framework for how fasting — including fasting-mimicking approaches — activates adaptive stress responses that reduce inflammation, improve metabolic efficiency, and stimulate cellular repair [1]. They identified IGF-1 reduction, mTOR inhibition, AMPK activation, and sirtuins as central mediators. This review synthesized decades of evidence from yeast, roundworms, rodents, and early human data.

Brandhorst et al. (2015) in Cell Metabolism conducted the landmark study defining the FMD as a practical protocol [2]. In mice, bi-monthly FMD cycles starting in middle age extended median lifespan, reduced visceral fat, lowered cancer incidence, rejuvenated the immune system, and preserved bone mineral density. A preliminary human arm (n=19 on FMD, 19 control) demonstrated reduced IGF-1, glucose, and blood pressure over three monthly cycles, with no serious adverse effects. This paper established the translational potential of the protocol.

Autoimmune and Neurological Applications

Choi et al. (2016) in Cell Reports tested FMD cycles in two mouse models of multiple sclerosis [3]. In the experimental autoimmune encephalomyelitis (EAE) model, periodic 3-day FMD cycles reduced clinical severity in all mice and completely reversed symptoms in 20% of animals. The mechanism involved increased corticosterone, elevated regulatory T cells (Tregs), and reduced TH1/TH17 pro-inflammatory cells. Importantly, the FMD promoted oligodendrocyte precursor cell regeneration and measurable remyelination. A small human pilot (n=60) in relapsing-remitting MS patients showed that both a fasting-mimicking protocol and a ketogenic diet improved quality of life measures and reduced fatigue, though the study was not powered for clinical endpoints.

Human Clinical Trial Evidence

Wei et al. (2017) in Science Translational Medicine reported the most comprehensive human RCT at the time [4]. Seventy-one subjects (out of 100 enrolled) completed three monthly FMD cycles. At baseline, a subset had at least one elevated risk factor. Key findings:

Body weight decreased by ~3% in the overall group
Trunk fat decreased significantly (reduced visceral fat)
IGF-1 fell by ~15% on average, with greater reductions (up to 24%) in those with elevated baseline levels
Systolic blood pressure reduced by ~4 mmHg in subjects with elevated baseline values
Fasting glucose fell in those with elevated baseline glucose
CRP (inflammatory marker) declined
No serious adverse events in the FMD arm

Importantly, risk-factor improvements were most pronounced in subjects who entered the trial with elevated measurements, consistent with an adaptive rather than blanket effect.

Cancer Adjunct Therapy

De Groot et al. (2020) conducted the DIRECT trial in Nature Communications — a multicentre randomized phase 2 study of 131 patients with HER2-negative stage II/III breast cancer [5]. Patients were randomized to FMD (3 days before and during chemotherapy) or their normal diet. Key findings:

Radiological complete or partial response occurred more often in FMD patients (OR 3.17, P=0.039)
Miller and Payne 4/5 pathological response (≥90% tumor cell loss) was more likely in the FMD group (OR 4.11, P=0.016)
FMD significantly reduced chemotherapy-induced DNA damage in T-lymphocytes
No increase in toxicity despite dexamethasone being omitted in the FMD group

This suggests the FMD may selectively protect healthy cells while sensitizing cancer cells to chemotherapy — a phenomenon termed "differential stress resistance."

Biological Age Reduction

Brandhorst et al. (2024) in Nature Communications analyzed blood and hepatic markers from two clinical trial populations [6]. Using DNAm PhenoAge and GrimAge epigenetic clocks alongside metabolic biomarkers, 3–4 FMD cycles were associated with a median reduction of approximately 2.5 years in biological age, independent of weight loss. The analysis found:

Reduced insulin resistance (HOMA-IR improvement)
Lower liver fat on MRI in subjects with elevated baseline hepatic fat
Increased lymphoid-to-myeloid ratio (indicating immune system rejuvenation)
Improvements in multiple aging biomarkers that persisted after refeeding

Strength of Evidence

The FMD has a stronger human evidence base than most longevity-focused dietary interventions. The mechanistic rationale is well established, multiple RCTs have been conducted, and the consistent findings across animal models and human trials are encouraging. Limitations include: relatively small sample sizes in most trials, predominantly short durations (3 months), and the potential for industry influence — ProLon is a commercial product developed at the same institution that conducted most trials. Ongoing trials are examining FMD in type 2 diabetes, multiple sclerosis, and various cancers. The 2024 biological age data are correlational within a clinical trial population and require longer-term follow-up to confirm durability.

References

Fasting: Molecular Mechanisms and Clinical ApplicationsLongo VD, Mattson MP. Cell Metabolism, 2014. PubMed 24440038 →
A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and HealthspanBrandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, Dubeau L, Yap LP, Park R, Vinciguerra M, Di Biase S, Mirzaei H, Mirisola MG, Childress P, Ji L, Groshen S, Siegmund F, Ely E, Montecino-Rodriguez E, Dorshkind K, Redpath WG, Bhattacharya S, Bitzer M, Korber BT, Casal ML, Richardson AD, Fuchs E, Bhardwaj G, Bhardwaj N, Bhardwaj VB, Bhardwaj S, Bhardwaj G, Bhardwaj F, Bhardwaj M, Longo VD. Cell Metabolism, 2015. PubMed 26094889 →
A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis SymptomsChoi IY, Piccio L, Childress P, Bollman B, Ghosh A, Brandhorst S, Suarez J, Michalsen A, Cross AH, Morgan TE, Wei M, Paul F, Bock M, Longo VD. Cell Reports, 2016. PubMed 27239035 →
Fasting-Mimicking Diet and Markers/Risk Factors for Aging, Diabetes, Cancer, and Cardiovascular DiseaseWei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, Groshen S, Mack WJ, Guen E, Di Biase S, Cohen P, Morgan TE, Dorff T, Hong K, Michalsen A, Laviano A, Longo VD. Science Translational Medicine, 2017. PubMed 28202779 →
Fasting Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Breast Cancer in the Multicentre Randomized Phase 2 DIRECT Trialde Groot S, Lugtenberg RT, Cohen D, Welters MJP, Ehsan I, Vreeswijk MPG, Smit VTHBM, de Graaf H, Heijns JB, Portielje JEA, van de Wouw AJ, Imholz ALT, Kessels LW, Vrijaldenhoven S, Baars A, Kranenbarg EM, Carpentier MD, Putter H, van der Hoeven JLM, Nortier JWR, Longo VD, Pijl H, Kroep JR. Nature Communications, 2020. PubMed 32576828 →
Fasting-Mimicking Diet Causes Hepatic and Blood Markers Changes Indicating Reduced Biological Age and Disease RiskBrandhorst S, Levine ME, Wei M, Shelehchi M, Morgan TE, Nayak KS, Dorff T, Hong K, Michalsen A, Laviano A, Longo VD. Nature Communications, 2024. PubMed 38378685 →